INVEST revisited: Review of findings from the International Verapamil SR-Trandolapril Study

Rhonda M. Cooper-DeHoff, Eileen M. Handberg, Giuseppe Mancia, Qian Zhou, Annette Champion, Udo F. Legler, Carl J. Pepine

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

The International Verapamil SR-Trandolapril Study (INVEST), a randomized trial of 22,576 predominantly elderly patients with an average 2.7-year follow-up, compared a calcium antagonist-led strategy (verapamil SR plus trandolapril) with a β-blocker-led strategy (atenolol plus hydrochlorothiazide) for hypertension treatment and prevention of cardiovascular outcomes in coronary artery disease patients. Patients received individualized dose and drug titration following a flexible, multi-drug, guideline-based treatment algorithm, with the objective of achieving optimal blood pressure (BP) control individualized for comorbidities (e.g., diabetes). The primary outcome (PO) was first occurrence of death (all-cause), nonfatal myocardial infarction or nonfatal stroke. The strategies resulted in significant and very similar BP reduction, with approximately 70% of patients in both strategies achieving BP control (

Original languageEnglish
Pages (from-to)1329-1340
Number of pages12
JournalExpert Review of Cardiovascular Therapy
Volume7
Issue number11
DOIs
Publication statusPublished - Nov 2009

Fingerprint

trandolapril
Verapamil
Blood Pressure
Hydrochlorothiazide
Atenolol
Pharmaceutical Preparations
Comorbidity
Coronary Artery Disease
Cause of Death
Stroke
Myocardial Infarction
Guidelines
Hypertension
Calcium
Therapeutics

Keywords

  • Atenolol
  • Coronary artery disease
  • Hydrochlorothiazide
  • Hypertension
  • INVEST
  • New-onset diabetes
  • Trandolapril
  • Verapamil SR

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Internal Medicine

Cite this

Cooper-DeHoff, R. M., Handberg, E. M., Mancia, G., Zhou, Q., Champion, A., Legler, U. F., & Pepine, C. J. (2009). INVEST revisited: Review of findings from the International Verapamil SR-Trandolapril Study. Expert Review of Cardiovascular Therapy, 7(11), 1329-1340. https://doi.org/10.1586/erc.09.102

INVEST revisited : Review of findings from the International Verapamil SR-Trandolapril Study. / Cooper-DeHoff, Rhonda M.; Handberg, Eileen M.; Mancia, Giuseppe; Zhou, Qian; Champion, Annette; Legler, Udo F.; Pepine, Carl J.

In: Expert Review of Cardiovascular Therapy, Vol. 7, No. 11, 11.2009, p. 1329-1340.

Research output: Contribution to journalArticle

Cooper-DeHoff, RM, Handberg, EM, Mancia, G, Zhou, Q, Champion, A, Legler, UF & Pepine, CJ 2009, 'INVEST revisited: Review of findings from the International Verapamil SR-Trandolapril Study', Expert Review of Cardiovascular Therapy, vol. 7, no. 11, pp. 1329-1340. https://doi.org/10.1586/erc.09.102
Cooper-DeHoff, Rhonda M. ; Handberg, Eileen M. ; Mancia, Giuseppe ; Zhou, Qian ; Champion, Annette ; Legler, Udo F. ; Pepine, Carl J. / INVEST revisited : Review of findings from the International Verapamil SR-Trandolapril Study. In: Expert Review of Cardiovascular Therapy. 2009 ; Vol. 7, No. 11. pp. 1329-1340.
@article{1f7c50d358dd46eaa567e7982200d455,
title = "INVEST revisited: Review of findings from the International Verapamil SR-Trandolapril Study",
abstract = "The International Verapamil SR-Trandolapril Study (INVEST), a randomized trial of 22,576 predominantly elderly patients with an average 2.7-year follow-up, compared a calcium antagonist-led strategy (verapamil SR plus trandolapril) with a β-blocker-led strategy (atenolol plus hydrochlorothiazide) for hypertension treatment and prevention of cardiovascular outcomes in coronary artery disease patients. Patients received individualized dose and drug titration following a flexible, multi-drug, guideline-based treatment algorithm, with the objective of achieving optimal blood pressure (BP) control individualized for comorbidities (e.g., diabetes). The primary outcome (PO) was first occurrence of death (all-cause), nonfatal myocardial infarction or nonfatal stroke. The strategies resulted in significant and very similar BP reduction, with approximately 70{\%} of patients in both strategies achieving BP control (",
keywords = "Atenolol, Coronary artery disease, Hydrochlorothiazide, Hypertension, INVEST, New-onset diabetes, Trandolapril, Verapamil SR",
author = "Cooper-DeHoff, {Rhonda M.} and Handberg, {Eileen M.} and Giuseppe Mancia and Qian Zhou and Annette Champion and Legler, {Udo F.} and Pepine, {Carl J.}",
year = "2009",
month = "11",
doi = "10.1586/erc.09.102",
language = "English",
volume = "7",
pages = "1329--1340",
journal = "Expert Review of Cardiovascular Therapy",
issn = "1477-9072",
publisher = "Expert Reviews Ltd.",
number = "11",

}

TY - JOUR

T1 - INVEST revisited

T2 - Review of findings from the International Verapamil SR-Trandolapril Study

AU - Cooper-DeHoff, Rhonda M.

AU - Handberg, Eileen M.

AU - Mancia, Giuseppe

AU - Zhou, Qian

AU - Champion, Annette

AU - Legler, Udo F.

AU - Pepine, Carl J.

PY - 2009/11

Y1 - 2009/11

N2 - The International Verapamil SR-Trandolapril Study (INVEST), a randomized trial of 22,576 predominantly elderly patients with an average 2.7-year follow-up, compared a calcium antagonist-led strategy (verapamil SR plus trandolapril) with a β-blocker-led strategy (atenolol plus hydrochlorothiazide) for hypertension treatment and prevention of cardiovascular outcomes in coronary artery disease patients. Patients received individualized dose and drug titration following a flexible, multi-drug, guideline-based treatment algorithm, with the objective of achieving optimal blood pressure (BP) control individualized for comorbidities (e.g., diabetes). The primary outcome (PO) was first occurrence of death (all-cause), nonfatal myocardial infarction or nonfatal stroke. The strategies resulted in significant and very similar BP reduction, with approximately 70% of patients in both strategies achieving BP control (

AB - The International Verapamil SR-Trandolapril Study (INVEST), a randomized trial of 22,576 predominantly elderly patients with an average 2.7-year follow-up, compared a calcium antagonist-led strategy (verapamil SR plus trandolapril) with a β-blocker-led strategy (atenolol plus hydrochlorothiazide) for hypertension treatment and prevention of cardiovascular outcomes in coronary artery disease patients. Patients received individualized dose and drug titration following a flexible, multi-drug, guideline-based treatment algorithm, with the objective of achieving optimal blood pressure (BP) control individualized for comorbidities (e.g., diabetes). The primary outcome (PO) was first occurrence of death (all-cause), nonfatal myocardial infarction or nonfatal stroke. The strategies resulted in significant and very similar BP reduction, with approximately 70% of patients in both strategies achieving BP control (

KW - Atenolol

KW - Coronary artery disease

KW - Hydrochlorothiazide

KW - Hypertension

KW - INVEST

KW - New-onset diabetes

KW - Trandolapril

KW - Verapamil SR

UR - http://www.scopus.com/inward/record.url?scp=73349138608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349138608&partnerID=8YFLogxK

U2 - 10.1586/erc.09.102

DO - 10.1586/erc.09.102

M3 - Article

C2 - 19900016

AN - SCOPUS:73349138608

VL - 7

SP - 1329

EP - 1340

JO - Expert Review of Cardiovascular Therapy

JF - Expert Review of Cardiovascular Therapy

SN - 1477-9072

IS - 11

ER -